
MEDIA RELEASE

Ypsomed is driving the digitisation of its portfolio

Burgdorf, 31.01.2018, 7 a.m. – Ypsomed continues to expand its offers for digital diabetes therapy with the launch of the mylife™ App. The mylife™ App is connected to the mylife™ YpsoPump® insulin pump via Bluetooth® and continuously records current therapy data. Digital therapy solutions add to customer benefit and increase the success of therapy long-term.

The mylife™ App stores the therapy data of the insulin pump and will be supplemented with data from blood glucose meters in the coming months. This way, the integrated bolus calculator can deliver therapy suggestions based on the most up-to-date therapy data. Digital solutions for therapy management offer users considerable advantages. The insulin dose is calculated discreetly on the smartphone and the therapy data no longer need to be recorded by hand. Furthermore, the data can be shared directly with medical professionals or caregivers via the link to Ypsomed's software and cloud solutions.

"The successful management of therapy is always based on up-to-date data. This makes it even more important to simplify the daily routine for people with diabetes and to adapt therapeutic management to today's and future lifestyles of users", comments Simon Michel, CEO of Ypsomed AG with regard to the digitisation of the product portfolio. Within this context, Ypsomed is presently advancing the mylife™ App to a control app for the mylife™ YpsoPump® and evaluates connectivity of sensor-based blood glucose monitoring systems. This means that the insulin pump will not only be read via the smartphone, but also controlled directly.

The introduction of the mylife™ App is linked directly to the product update of the mylife™ YpsoPump® insulin pump and will be available in 16 European countries by the end of April 2018, including Germany, Italy, the UK, France and Switzerland.

For further information, please contact Thomas Kutt, Head of Investor Relations at Ypsomed Holding AG, at the telephone number +41 34 424 35 55 or by e-mail (thomas.kutt@ypsomed.com).

The Bluetooth® word mark and logos are registered trademarks belonging to Bluetooth SIG, Inc., and all use of such marks by Ypsomed AG is licensed. Other trademarks and trade names are property of their respective owners.

About the Ypsomed Group

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1'500 employees. Additional information is available under www.ypsomed.com.